Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Biotech·Bambusa Therapeutics

Bambusa Therapeutics raises $169M in upsized Nasdaq IPO priced at $16 a share

The Boston developer of long-acting bispecific antibodies for inflammatory diseases sold 10.6 million shares at the midpoint of its range. Its share count implies a market value of about $815 million at the IPO price.

From a company announcement published Oct. 29, 2026, and the company's amended registration statement (Form S-1/A) filed Oct. 26, 2026
A wall of market-data screens at the Nasdaq MarketSite studio in New York in 2006.
A wall of market-data screens at the Nasdaq MarketSite studio in New York in 2006. File photo.Luis Villa del Campo / Wikimedia Commons (CC BY 2.0)
Amount
$169M
Type
IPO
Company
Bambusa Therapeutics
Sector
Biotech
Announced
Oct. 29, 2026

Bambusa Therapeutics went public about two and a half years after it was formed, and it sold more stock than it first planned. The Boston company said Oct. 29 that it priced an upsized IPO of 10,555,555 shares at $16 each, raising about $168.9 million before fees.

The price was the midpoint of the $15 to $17 range Bambusa set in an amended registration statement filed Oct. 26, when it planned to sell 9,375,000 shares. Underwriters have 30 days to buy up to 1,583,333 more. Every share in the deal was sold by the company, and trading was set to begin Oct. 30 on the Nasdaq Global Select Market under the ticker BBTX.

Why it matters: Bambusa is a clinical-stage immunology company whose two clinical programs were acquired from a BioNTech subsidiary. Public investors bought in at a size above the original plan, at the midpoint of the price range.

BofA Securities, Evercore ISI, UBS Investment Bank and Cantor were joint book-running managers.

The numbers in the prospectus

Bambusa's amended registration statement put its share count before the offering at 40,386,875, as of June 30 and after the conversion of its preferred stock. Adding the 10,555,555 shares sold brings the total to 50,942,430, which at $16 a share implies a market value of about $815 million before any exercise of the underwriters' option.

The preliminary prospectus earmarks about $90 million for the lead candidate, BBT001, including a planned Phase 2b study in atopic dermatitis, and about $40 million for the second candidate, BBT002, including an expected Phase 2b trial in a respiratory indication. The rest goes to two preclinical programs, BBT003 and BBT004, and general corporate purposes. Bambusa said the IPO proceeds and its existing cash should fund operations into late 2028.

Before the offering, Bambusa reported $71.5 million in cash, cash equivalents and marketable securities as of June 30. It lost $22.4 million in the first half of 2026 and $41.1 million in 2025, and had an accumulated deficit of $77.2 million at midyear.

Where the drugs came from

Bambusa was incorporated in Delaware in March 2024. It acquired the assets behind BBT001 and BBT002 from a BioNTech subsidiary in Zhuhai, China, then known as Biotheus, according to the preliminary prospectus. Shanshan Xu, its co-founder, president and chief executive, was previously head of global external innovations at BioNTech.

The company describes BBT001 as a bispecific antibody that targets IL-4Rα and IL-31 and uses half-life extension technology meant to allow longer dosing intervals. It is in a global Phase 1 trial in moderate-to-severe atopic dermatitis, and in July Bambusa reported what it called positive topline proof-of-concept results from that study. BBT002 targets IL-4Rα and IL-5 and is in early trials for chronic obstructive pulmonary disease and, in China, chronic rhinosinusitis with nasal polyps, the company said.

What to watch

Bambusa said it expects several more BBT001 data readouts through the first half of 2027. Those results and the start of the two Phase 2b trials the IPO is meant to fund are the next milestones the company has laid out. The company said the offering was expected to close Nov. 2.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Biotech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.